The HPV testing & PAP test market is expected to witness rapid growth due to the increasing number of cervical cancer cases across the globe, an increasing number of cervical cancer screening programs and the introduction of advanced technologies
Cervical cancer is found to be one of the major causes of cancer-related deaths in the women population. As per the American Society of Clinical Oncology, cervical cancer tends to occur in midlife and is most frequently diagnosed in women between the ages of 35 and 44 years. More than 15% of cervical cancer cases are found in women aged more than 65 years. According to the American Cancer Society's estimates, about 13,170 new cases of invasive cervical cancer may be diagnosed and about 4,250 women may die from cervical cancer in the United States, in 2019.
Additionally, according to WHO, cervical cancer is the fourth most frequent cancer in women, with an estimated 570,000 new cases in 2018, representing 6.6% of all female cancers. Approximately, 90% of deaths from cervical cancer occur in middle- to low-income countries. The growing number of cervical cancer cases results in the need for new, technically advanced, and less expensive screening programs. There are also government and regional authorities that are implementing certain initiatives that drive the demand for cancer detections tests and kits. Therefore the increasing number of cases of cervical cancer and initiatives has boosted the demand for HPV testing and PAP testing market.
Key Market Trends
Cervical Cancer Screening Test is Expected to be the Dominant Over the Forecast Period
Cervical cancer screening is found to be an essential part of a woman’s routine health care. The primary goal of screening is to identify precancerous lesions caused by HPV so they can be removed to prevent invasive cancers from developing.
Cervical cancer screening tests segment is found dominating the segment owing to the increasing awareness about the benefits associated with the early detection of cancer and the growing government support towards controlling the incidence rate of late-stage cervical cancer. It is known that in most cases, cervical cancer is caused by infection with sexually transmitted oncogenic, or high-risk, types of HPV. There are about a dozen high-risk HPV types, and just two of these, HPV types 16 and 18, are responsible for about 70% of all cervical cancers. For women aged 30 and above, an HPV test is also recommended for the detection. HPV tests can find any of the high-risk types of HPV that are commonly found in cervical cancer. Hence, these factors are expected to drive the market growth.
North America Region Expected to Dominate the Market of HPV Testing & PAP Test Over the Forecast Period
North America region has been found dominating the market in terms of revenue due to the increased number of cervical cancer cases and the growing awareness among women due to the various government initiatives and research studies that were undertaken.
According to WHO, cervical cancer is the fourth most frequent cancer in women and in 2018, around 5,70,000 new cervical cases were being diagnosed, thus the rising patient pool will drive the overall market growth. The Centers for Disease Control (CDC) estimates that about 79 million people are currently infected with HPV in the United States, and about 14 million people in the US get infected with new HPV infections every year. Thus the increasing number of cervical cancer cases has boosted the demand for HPV testing and Pap testing market.
Additionally, the favorable trade policies in the United States lowers the entry barriers for new players willing to capture considerable market share in the HPV testing and Pap test market.
Some key players in the HPV test and Pap test market include Abbott Laboratories, Qiagen, Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd, and many others. The industry players present in the market are found focussing on strategies such as mergers and acquisitions to expand the existing product portfolio. Also, the receiving approvals from regulatory authorities for new product launches will render the company with a competitive advantage.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support